The present work, using samples from the tumour bank of a referring cancer centre, demonstrates that PSMA expression is negligible and a fortiori non-sufficient to ensure its usefulness as a prognosticator or a target for a theranostic strategy in ovarian cancers. This evidence concerns the gene FOLH1 and neoplasm.